Imaging-Based Biomarkers Predict Programmed Death-Ligand 1 and Survival Outcomes in Advanced NSCLC Treated With Nivolumab and Pembrolizumab: A Multi-Institutional Study

Imaging-Based Biomarkers Predict Programmed Death-Ligand 1 and Survival Outcomes in Advanced NSCLC Treated With Nivolumab and Pembrolizumab: A Multi-Institutional Study

Background: Although the immune checkpoint inhibitors, nivolumab and pembrolizumab, were found to be promising in patients with advanced NSCLC, some of them either do not respond or have recurrence after an initial response. It is still unclear who will benefit from these therapies, and, hence, ther...

Full description

Bibliographic Details
Main Authors: Sevinj Yolchuyeva, PhD, Elena Giacomazzi, MSc, Marion Tonneau, PhD, Fabien Lamaze, PhD, Michele Orain, MT, François Coulombe, MD, Julie Malo, CCRP, Wiam Belkaid, PhD, Bertrand Routy, MD, PhD, Philippe Joubert, MD, PhD, Venkata S.K. Manem, MSc, PhD
Format: Article
Language:English
Published: Elsevier 2023-12-01
Series:JTO Clinical and Research Reports
Subjects:
Radiomics
Machine learning
Immunotherapy
Biomarker discovery
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364323001455

Internet

http://www.sciencedirect.com/science/article/pii/S2666364323001455

Similar Items